Tobin Schilke - 02 Feb 2022 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CFO
Signature
/s/ Terri McDowell, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
02 Feb 2022
Net transactions value
$0
Form type
4
Filing time
04 Feb 2022, 19:31:58 UTC
Previous filing
04 Jan 2022
Next filing
17 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVNC Employee Stock Option (Right to Buy) Award $0 +68,093 $0.000000 68,093 02 Feb 2022 Common Stock 68,093 $13.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2022, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.